Maria L Ceretta1, Marlies Noordzij2, Rosario Luxardo3, Johan De Meester4, Jose M Abad Diez5, Patrik Finne6,7, James G Heaf8, Cécile Couchoud9, Reinhard Kramar10, Frederic Collart11, Aleix Cases12,13, Runolfur Palsson14,15, Anna V Reisæter16, Helena Rydell17,18,19, Ziad A Massy20,21, Kitty J Jager2, Anneke Kramer2. 1. Uruguayan Dialysis Registry, Uruguayan Society of Nephrology, Montevideo, Uruguay. 2. ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands. 3. Nephrology Service, Hospital Italiano de Buenos Aires, CABA, Buenos Aires, Argentina. 4. Department of Nephrology, Dialysis and Hypertension, Dutch-speaking Belgian Renal Registry (NBVN), Sint-Niklaas, Belgium. 5. Servicio Aragonés de la Salud, Gobierno de Aragón, Zaragoza, Spain. 6. Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 7. Finnish Registry for Kidney Diseases, Helsinki, Finland. 8. Department of Medicine, Zealand University Hospital, Roskilde, Denmark. 9. REIN Registry, Agence de la biomédecine, Saint-Denis La Plaine, France. 10. Austrian Dialysis and Transplant Registry, Rohr, Austria. 11. French-Belgian ESRD Registry, Brussels, Belgium. 12. Nephrology Unit Hospital Clinic, Barcelona, Spain. 13. Registre de Malalts Renals de Catalunya, Barcelona, Spain. 14. Division of Nephrology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland. 15. Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland. 16. Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway. 17. Swedish Renal Registry, Jönköping, Sweden. 18. Lund University, Lund, Sweden. 19. Skane University Hospital, Lund, Sweden. 20. Division of Nephrology, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt, Paris, France. 21. Institut National de la Santé et de la Recherche Médicale (INSERM) Unit 1018 team 5, Research Centre in Epidemiology and Population Health (CESP), University of Paris Ouest-Versailles-St Quentin-en-Yveline, Villejuif, France.
Abstract
Background: Patients starting renal replacement therapy (RRT) for end-stage renal disease often present with one or more co-morbidities. This study explored the prevalence of co-morbidities in patients who started RRT in Europe during the period from 2005 to 2014. Methods: Using data from patients aged 20 years or older from all 11 national or regional registries providing co-morbidity data to the European Renal Association - European Dialysis and Transplant Association Registry, we examined the prevalence of the following co-morbidities: diabetes mellitus (DM) (primary renal disease and/or co-morbidity), ischaemic heart disease (IHD), congestive heart failure (CHF), peripheral vascular disease (PVD), cerebrovascular disease (CVD) and malignancy. Results: Overall, 70% of 7578 patients who initiated RRT in 2014 presented with at least one co-morbidity: 39.0% presented with DM, 25.0% with IHD, 22.3% with CHF, 17.7% with PVD, 16.4% with malignancy and 15.5% with CVD. These percentages differed substantially between countries. Co-morbidities were more common in men than in women, in older patients than in younger patients, and in patients on haemodialysis at Day 91 when compared with patients on peritoneal dialysis. Between 2005 and 2014 the prevalence of DM and malignancy increased over time, whereas the prevalence of IHD and PVD declined. Conclusions: More than two-thirds of patients initiating RRT in Europe have at least one co-morbidity. With the rising age at the start of RRT over the last decade, there have been changes in the co-morbidity pattern: the prevalence of cardiovascular co-morbidities decreased, while the prevalence of DM and malignancy increased.
Background: Patients starting renal replacement therapy (RRT) for end-stage renal disease often present with one or more co-morbidities. This study explored the prevalence of co-morbidities in patients who started RRT in Europe during the period from 2005 to 2014. Methods: Using data from patients aged 20 years or older from all 11 national or regional registries providing co-morbidity data to the European Renal Association - European Dialysis and Transplant Association Registry, we examined the prevalence of the following co-morbidities: diabetes mellitus (DM) (primary renal disease and/or co-morbidity), ischaemic heart disease (IHD), congestive heart failure (CHF), peripheral vascular disease (PVD), cerebrovascular disease (CVD) and malignancy. Results: Overall, 70% of 7578 patients who initiated RRT in 2014 presented with at least one co-morbidity: 39.0% presented with DM, 25.0% with IHD, 22.3% with CHF, 17.7% with PVD, 16.4% with malignancy and 15.5% with CVD. These percentages differed substantially between countries. Co-morbidities were more common in men than in women, in older patients than in younger patients, and in patients on haemodialysis at Day 91 when compared with patients on peritoneal dialysis. Between 2005 and 2014 the prevalence of DM and malignancy increased over time, whereas the prevalence of IHD and PVD declined. Conclusions: More than two-thirds of patients initiating RRT in Europe have at least one co-morbidity. With the rising age at the start of RRT over the last decade, there have been changes in the co-morbidity pattern: the prevalence of cardiovascular co-morbidities decreased, while the prevalence of DM and malignancy increased.
Authors: Gurbey Ocak; Rianne Boenink; Marlies Noordzij; Willem Jan W Bos; Bjorn E Vikse; Aleix Cases; Julia Kerschbaum; Jaakko Helve; Maurizio Nordio; Mustafa Arici; Lucile Mercadal; Christoph Wanner; Runolfur Palsson; Kristine Hommel; Johan De Meester; Myrto Kostopoulou; Rafael Santamaria; Emilio Rodrigo; Helena Rydell; Samira Bell; Ziad A Massy; Kitty J Jager; Anneke Kramer Journal: JAMA Netw Open Date: 2022-04-01
Authors: Hsiu-Lan Li; Pei-Hui Tai; Yi-Ting Hwang; Shih-Wei Lin; Li-Ching Lan Journal: Int J Environ Res Public Health Date: 2022-08-18 Impact factor: 4.614